Caliber Imaging & Diagnostics EBIT per Share
The EBIT per Share of Caliber Imaging & Diagnostics (LCDX) as of Aug 14, 2026 is -0.58 USD.
Get this data via API
Financial Data API
EBIT per Share
-0.58USD
Last updated:
EBIT per Share of Caliber Imaging & Diagnostics is 2026 -0.58 USD. EBIT per Share of Caliber Imaging & Diagnostics was 2025 - USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Caliber Imaging & Diagnostics Stock analysis
What does Caliber Imaging & Diagnostics do? Caliber Imaging & Diagnostics Inc (CID), founded in 2007, is a medical technology company based in Rochester, New York. CID focuses on the development of optical imaging systems used in the diagnosis of tissue and skin diseases.
CID was founded by an experienced leadership team who previously worked at Kodak and focused on developing new imaging technologies. The founders of CID recognized a significant unmet need in the diagnosis of skin diseases, as traditional methods such as biopsies are painful and invasive.
Therefore, CID developed a revolutionary technology called VivaScope® that provides a non-invasive, painless method of tissue imaging. This technology allows doctors to make rapid decisions about a patient without having to wait for a biopsy.
CID aims to distribute its products in the North American market and expand its presence in other regions such as Europe, Asia, and the Middle East. The company aims to benefit from the growing trends in telemedicine and the widespread use of telemedicine tools and wearables.
CID has built trusted relationships with many renowned clinics and medical institutes worldwide to test and validate its VivaScope® technology and increase its industry recognition.
CID focuses on providing technologies for the diagnosis of skin diseases and tissues. The VivaScope technology is capable of visualizing tissue structures beneath the skin surface at magnifications of up to 1000x.
CID offers three main products: VivaScope® System, VivaScope® 1500, and VivaScope® 3000. The VivaScope® system is an advanced diagnostic system approved by the FDA. It uses advanced optics and VegascanTM software to provide TissueMap™ images, allowing doctors to visualize tissue beneath the skin surface.
The VivaScope® 1500 is a portable version of the VivaScope® system used for diagnosing superficial skin diseases such as melanomas, basal cell carcinomas, and actinic keratoses. The VivaScope® 3000 is CID's latest product, offering higher resolution and better image quality than the VivaScope® system or the VivaScope® 1500.
The VivaScope® system has been developed to enable fast, painless, and non-invasive diagnosis of skin diseases. The technology of the VivaScope® system allows doctors to visualize tissue structures and cellular changes beneath the skin surface, which can help reduce the number of painful skin biopsies.
VivaScope® 1500 is a handheld version of the VivaScope® system that is easy to transport and provides doctors with a mobile diagnostic capability. This device is ideal for examining superficial skin diseases such as melanomas, basal cell carcinomas, and actinic keratoses.
The VivaScope® 3000 is CID's latest product. This advanced diagnostic system offers higher resolution and better image quality than the VivaScope® system and the VivaScope® 1500. The VivaScope® 3000 features the latest technology and can be used for analyzing skin and tissue.
In conclusion, CID is an innovative company specializing in the development of optical imaging systems. The company has developed a revolutionary technology called VivaScope, which helps reduce painful skin biopsies and enables doctors to make quick decisions. With a strong presence in the North American market and growing interest in telemedicine, CID has all the prerequisites to become a key player in a rapidly evolving industry. Caliber Imaging & Diagnostics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Caliber Imaging & Diagnostics stock
EBIT per Share of Caliber Imaging & Diagnostics is -0.58 USD in 2026.
On Eulerpool you can find the complete historical development of EBIT per Share Caliber Imaging & Diagnostics since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Caliber Imaging & Diagnostics
All Key Metrics — Caliber Imaging & Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth